These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
965 related articles for article (PubMed ID: 11922664)
1. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease. Cunningham LA; Su C Exp Neurol; 2002 Apr; 174(2):230-42. PubMed ID: 11922664 [TBL] [Abstract][Full Text] [Related]
2. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease. Ericson C; Georgievska B; Lundberg C Eur J Neurosci; 2005 Dec; 22(11):2755-64. PubMed ID: 16324109 [TBL] [Abstract][Full Text] [Related]
3. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Bensadoun JC; Déglon N; Tseng JL; Ridet JL; Zurn AD; Aebischer P Exp Neurol; 2000 Jul; 164(1):15-24. PubMed ID: 10877911 [TBL] [Abstract][Full Text] [Related]
5. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease. Mandel RJ; Snyder RO; Leff SE Exp Neurol; 1999 Nov; 160(1):205-14. PubMed ID: 10630205 [TBL] [Abstract][Full Text] [Related]
6. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Choi-Lundberg DL; Lin Q; Schallert T; Crippens D; Davidson BL; Chang YN; Chiang YL; Qian J; Bardwaj L; Bohn MC Exp Neurol; 1998 Dec; 154(2):261-75. PubMed ID: 9878166 [TBL] [Abstract][Full Text] [Related]
7. Astrocytes promote or impair the survival and function of embryonic ventral mesencephalon co-grafts: effects of astrocyte age and expression of recombinant brain-derived neurotrophic factor. Krobert K; Lopez-Colberg I; Cunningham LA Exp Neurol; 1997 Jun; 145(2 Pt 1):511-23. PubMed ID: 9217087 [TBL] [Abstract][Full Text] [Related]
8. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease. Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539 [TBL] [Abstract][Full Text] [Related]
9. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079 [TBL] [Abstract][Full Text] [Related]
10. Implantation of bioactive growth factor-secreting rods enhances fetal dopaminergic graft survival, outgrowth density, and functional recovery in a rat model of Parkinson's disease. Törnqvist N; Björklund L; Almqvist P; Wahlberg L; Strömberg I Exp Neurol; 2000 Jul; 164(1):130-8. PubMed ID: 10877923 [TBL] [Abstract][Full Text] [Related]
11. Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. Piltonen M; Bespalov MM; Ervasti D; Matilainen T; Sidorova YA; Rauvala H; Saarma M; Männistö PT Exp Neurol; 2009 Oct; 219(2):499-506. PubMed ID: 19615368 [TBL] [Abstract][Full Text] [Related]
12. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Connor B; Kozlowski DA; Schallert T; Tillerson JL; Davidson BL; Bohn MC Gene Ther; 1999 Dec; 6(12):1936-51. PubMed ID: 10637445 [TBL] [Abstract][Full Text] [Related]
13. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum. Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795 [TBL] [Abstract][Full Text] [Related]
14. Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease. Do Thi NA; Saillour P; Ferrero L; Dedieu JF; Mallet J; Paunio T Gene Ther; 2004 May; 11(9):746-56. PubMed ID: 14724667 [TBL] [Abstract][Full Text] [Related]
15. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Wang L; Muramatsu S; Lu Y; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Hanazono Y; Kume A; Urano F; Ichinose H; Nagatsu T; Nakano I; Ozawa K Gene Ther; 2002 Mar; 9(6):381-9. PubMed ID: 11960314 [TBL] [Abstract][Full Text] [Related]
16. Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson's disease? Do Thi NA; Saillour P; Ferrero L; Paunio T; Mallet J Gene Ther; 2007 Mar; 14(5):441-50. PubMed ID: 17093508 [TBL] [Abstract][Full Text] [Related]